{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:31Z","timestamp":1792813531618,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) recipients are susceptible to viral infections. We conducted a phase 2 trial evaluating the safety and rate of clinically significant infections (CSIs; viremia requiring treatment or end-organ disease) after infusion of posoleucel, a partially HLA-matched, allogeneic, off-the-shelf, multivirus-specific T-cell investigational product for preventing CSIs with adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, or JC virus. This open-label trial enrolled allo-HCT recipients at high risk based on receiving grafts from umbilical cord blood, haploidentical, mismatched, or matched unrelated donors; post-HCT lymphocytes of &amp;lt;180\/mm3; or use of T-cell depletion. Posoleucel dosing was initiated within 15 to 49\u00a0days of allo-HCT and subsequently every 14\u00a0days for up to 7 doses. The primary end point was the number of CSIs due to the 6 target viruses by week 14. Of the 26 patients enrolled, only 3\u00a0(12%) had a CSI by week 14, each with a single target virus. In\u00a0vivo expansion of functional virus-specific T cells detected via interferon-\u03b3 enzyme-linked immunosorbent\u00a0spot assay was associated with viral control. Persistence of posoleucel-derived T-cell clones for up to 14\u00a0weeks after the last infusion was confirmed by T-cell\u2013receptor deep sequencing. Five patients (19%) had acute graft-versus-host disease grade 2 to 4. No patient experienced cytokine release syndrome. All 6 deaths were due to relapse or disease progression. allo-HCT recipients at high risk who received posoleucel had low rates of CSIs from 6 targeted viruses. Repeat posoleucel dosing was generally safe and well tolerated and associated with functional immune reconstitution. This trial was registered at www.ClinicalTrials.gov as #NCT04693637.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011562","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T18:53:31Z","timestamp":1712688811000},"page":"4740-4750","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients"],"prefix":"10.1182","volume":"8","author":[{"given":"Sanjeet S.","family":"Dadwal","sequence":"first","affiliation":[{"name":"1Division of Infectious Disease, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Bansal","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Schuster","sequence":"additional","affiliation":[{"name":"3Bone Marrow and Stem Cell Transplantation, Stony Brook University Hospital Cancer Center, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"4Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Douglas","family":"Myers","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Children's Mercy of Kansas City, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-0826","authenticated-orcid":false,"given":"Michelle","family":"Matzko","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Adnan","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McNeel","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ma","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Gilmore","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Vasileiou","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"},{"name":"7Baylor College of Medicine, Texas Children\u2019s Hospital and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Leen","sequence":"additional","affiliation":[{"name":"6AlloVir, Waltham, MA"},{"name":"7Baylor College of Medicine, Texas Children\u2019s Hospital and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-9834","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[{"name":"8Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"9University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-341X","authenticated-orcid":false,"given":"Jo-Anne H.","family":"Young","sequence":"additional","affiliation":[{"name":"10Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"2024091015211453600_bib1","unstructured":"Auletta\n              JJ\n            , KouJ, ChenM, ShawBE. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. CIBMTR. 2021. Accessed 23 December 2023. https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports."},{"issue":"5","key":"2024091015211453600_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2024091015211453600_bib3","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024091015211453600_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, non-relapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 vs. 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"24","key":"2024091015211453600_bib5","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2024091015211453600_bib6","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024091015211453600_bib7","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/acg2.29","article-title":"Advances in ex\u00a0vivo T cell depletion \u2013 where do we stand?","volume":"2","author":"Bryant","year":"2019","journal-title":"Adv Cell Gene Ther"},{"issue":"9","key":"2024091015211453600_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jcyt.2022.05.010","article-title":"Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment","volume":"24","author":"Stanojevic","year":"2022","journal-title":"Cytotherapy"},{"issue":"2","key":"2024091015211453600_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2024091015211453600_bib10","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2024091015211453600_bib11","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024091015211453600_bib12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024091015211453600_bib13","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024091015211453600_bib14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.bbmt.2019.05.020","article-title":"Characterization of viral infections after antithymocyte globulin-based conditioning in adults undergoing allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Figgins","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024091015211453600_bib15","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"2024091015211453600_bib16","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2024091015211453600_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1756-8722-6-94","article-title":"Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Lin","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024091015211453600_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.idc.2021.11.004","article-title":"Antiviral therapeutics in pediatric transplant recipients","volume":"36","author":"Otto","year":"2022","journal-title":"Infect Dis Clin North Am"},{"key":"2024091015211453600_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In\u00a0vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antiviral Res"},{"key":"2024091015211453600_bib20","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res"},{"issue":"4","key":"2024091015211453600_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"2024091015211453600_bib22","doi-asserted-by":"crossref","first-page":"e13515","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"16","key":"2024091015211453600_bib23","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/bloodadvances.2021004362","article-title":"Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients","volume":"5","author":"Hill","year":"2021","journal-title":"Blood Adv"},{"key":"2024091015211453600_bib24","doi-asserted-by":"crossref","first-page":"567531","DOI":"10.3389\/fimmu.2020.567531","article-title":"Harnessing T cells to control infections after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Basso","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2024091015211453600_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cells8010047","article-title":"Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic stem cell transplantation","volume":"8","author":"Ottaviano","year":"2019","journal-title":"Cells"},{"issue":"3","key":"2024091015211453600_bib26","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"9","key":"2024091015211453600_bib27","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024091015211453600_bib28","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2022008219","article-title":"Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease","volume":"7","author":"Kinoshita","year":"2023","journal-title":"Blood Adv"},{"key":"2024091015211453600_bib29","doi-asserted-by":"crossref","first-page":"1251593","DOI":"10.3389\/fimmu.2023.1251593","article-title":"Prevention of CMV\/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I\/IIa MULTIVIR-01 study","volume":"14","author":"Gerbitz","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"2024091015211453600_bib30","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2024091015211453600_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"242","key":"2024091015211453600_bib32","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV-6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"31","key":"2024091015211453600_bib33","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024091015211453600_bib34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multi-virus specific T cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2024091015211453600_bib35","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1097\/TXD.0000000000000787","article-title":"Impact of CMV PCR blips in recipients of solid organ and hematopoietic stem cell transplantation","volume":"4","author":"Lodding","year":"2018","journal-title":"Transplant Direct"},{"issue":"554","key":"2024091015211453600_bib36","doi-asserted-by":"crossref","first-page":"eaaz3339","DOI":"10.1126\/scitranslmed.aaz3339","article-title":"The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma","volume":"12","author":"Lulla","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"2024091015211453600_bib37","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.celrep.2018.11.009","article-title":"Identifying and tracking low-frequency virus-specific TCR clonotypes using high-throughput sequencing","volume":"25","author":"Wolf","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"2024091015211453600_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2024091015211453600_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3947\/ic.2018.50.2.153","article-title":"Cytomegalovirus colitis during dasatinib treatment for patients with hematologic malignancy: case series and literature review","volume":"50","author":"Choi","year":"2018","journal-title":"Infect Chemother"},{"issue":"6","key":"2024091015211453600_bib40","doi-asserted-by":"crossref","first-page":"505.e1","DOI":"10.1016\/j.jtct.2021.02.021","article-title":"Economic and clinical burden of virus-associated hemorrhagic cystitis in patients following allogeneic hematopoietic stem cell transplantation in the United States","volume":"27","author":"McGuirk","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024091015211453600_bib41","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.jtct.2022.06.016","article-title":"Clinical and economic burden of multiple double-stranded DNA viral infections after allogeneic hematopoietic cell transplantation","volume":"28","author":"Hill","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024091015211453600_bib42","first-page":"204993612110180","article-title":"Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus","volume":"8","author":"Wang","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"3","key":"2024091015211453600_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/infdis\/jiab412","article-title":"Human herpesvirus 6 DNAemia is associated with worse survival after ex\u00a0vivo T-cell-depleted hematopoietic cell transplant","volume":"225","author":"Lee","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2024091015211453600_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024091015211453600_bib45","first-page":"120","article-title":"Adverse effects of virus-specific T-cell therapy: an integrative review","volume":"10","author":"Simmons","year":"2019","journal-title":"J\u00a0Adv Pract Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4740\/2241106\/blooda_adv-2023-011562-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4740\/2241106\/blooda_adv-2023-011562-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:22:20Z","timestamp":1725981740000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4740\/515666\/Final-outcomes-from-a-phase-2-trial-of-posoleucel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011562","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}